Indeed no surprise really, profit as per usual for the giant. Part of their strategy; risk = reward. Good case in point here, eventually we'll all be paid off for it imo.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
